What is Dyne Therapeutics, Inc.'s interest coverage?

Dyne Therapeutics, Inc. (DYN) reported interest coverage of -45.3× in Q1 2026.

What does interest coverage mean?

Trailing-twelve-month operating income (EBIT) divided by interest expense. Measures how many times over the company can cover its interest payments from operating profit.

Dyne Therapeutics, Inc. DYN Interest coverage

Interest coverage at other companies

Ionis PharmaceuticalsIONS

-19.2×-4.6×

Arrowhead ResearchARWR

-2.4×+0.9×

Scholar RockSRRK

-55.5×+40.2×

Cogent Biosciences, Inc.COGT

-84.7×—

Krystal Biotech, Inc.KRYS

6.2×+2.5×

Acadia PharmaceuticalsACAD

2.5×-5.9×

Other financials

Income statement

See full

Operating income-$125.3M-2.4%

Net income-$120.9M-4.8%

EPS (diluted)-$0.73+30.5%

Balance sheet

See full

Cash & equivalents$753.1M+59.5%

Total debt$168.7M+623%

Total equity$865.1M+29.3%

Total assets$1.1B+49.8%

Cash flow

See full

Operating cash flow-$144.9M-36.9%

CapEx$221.0K-77.5%

Free cash flow-$145.1M-35.8%

Valuation

See full

Market cap$3.35B+153%

Returns & leverage

See full

Return on equity-58.9%-4.4pp

Debt / equity0.2×+0.2×

Current ratio19.9×-0.4×

Where this comes from

Calculated from Dyne Therapeutics, Inc.’s reported figures.

ebit/interest expense=-45.3×

Based on trailing twelve months.

The official record: Dyne Therapeutics, Inc.’s 10-Q, filed May 11, 2026, on SEC EDGAR. View the filing →

Ask your AI about Dyne Therapeutics, Inc.'s interest coverage.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Dyne Therapeutics, Inc.'s interest coverage?: Dyne Therapeutics, Inc. (DYN) reported interest coverage of -45.3× in Q1 2026.
What does interest coverage mean?: Trailing-twelve-month operating income (EBIT) divided by interest expense. Measures how many times over the company can cover its interest payments from operating profit.